Japan’s ABsize Gets U.S. FDA Clearance For Phase I Pain-Patch Trials

Japanese biotech ABsize received clearance from U.S. FDA to conduct clinical trials of its AB001 anti-inflammatory transdermal patch for sprains and other acute pain.

ABsize is a bioventure specializing in nanotechnology and nanomedicine spun off by Osaka University. U.S. Phase I trials could be started by the end of the year, followed by an ABsize search for a partner to carry the patch to Phase II trials and beyond. ABsize is aiming for a 2013 U.S. launch of its patch. (Click here for more – a subscription may be required

)

More from Japan

More from Focus On Asia